TY - JOUR AU - Wood, Paul L. AU - Smith, Tara AU - Lane, Nina AU - Khan, M. Amin AU - Ehrmantraut, Greg AU - Goodenowe, Dayan B. PY - 2011 DA - 2011/12/05 TI - Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease JO - Lipids in Health and Disease SP - 227 VL - 10 IS - 1 AB - Docosahexaenoic acid (DHA) and DHA-containing ethanolamine plasmalogens (PlsEtn) are decreased in the brain, liver and the circulation in Alzheimer's disease. Decreased supply of plasmalogen precursors to the brain by the liver, as a result of peroxisomal deficits is a process that probably starts early in the AD disease process. To overcome this metabolic compromise, we have designed an orally bioavailable DHA-containing ether lipid precursor of plasmalogens. PPI-1011 is an alkyl-diacyl plasmalogen precursor with palmitic acid at sn-1, DHA at sn-2 and lipoic acid at sn-3. This study outlines the oral pharmacokinetics of this precursor and its conversion to PlsEtn and phosphatidylethanolamines (PtdEtn). SN - 1476-511X UR - https://doi.org/10.1186/1476-511X-10-227 DO - 10.1186/1476-511X-10-227 ID - Wood2011 ER -